Crestline Management, L.P. — Q4 2025 13F-HR

← Crestline Management, L.P.

Q4 2025 · 13F-HR

Crestline Management, L.P.holdings as filed

Filed 2026-02-17 · accession 0001315863-26-000165

$53.3M

Reported value

Positions

2025-12-31

Period end

View analyzed profile →PRO

The Brief · Crestline Management, L.P. · Q4 2025

AI · grounded in 13F

Crestline Management, L.P. reduced its position in SANA by 32.95%. The fund also trimmed its holding in DNLI by 17.59%. These moves brought the fund's total position count to 3 with total AUM of $53.3M.

Holdings as filed

CUSIP	Ticker	Issuer	Value	% port.	Shares	Class	Voting
24823R105	DNLI	DENALI THERAPEUTICS INC	$46.4M	87.0%	2,810,732	Common	SOLE
799566104	SANA	SANA BIOTECHNOLOGY INC	$5.0M	9.32%	1,220,937	Common	SOLE
282914100	EGHT	8X8 INC NEW	$2.0M	3.66%	990,580	Common	SOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.